ADOCIA a biotechnology company dedicated to protein delivery

  • Contact
  • Linkedin
  • Twitter
  • Youtube
  • RSS
  • LANGUAGES
    • English English
    • Français Français
  • Presentation
    • About Adocia
    • Founders
    • Management
    • Board of Directors
    • Team
    • Scientific Advisory Board
    • Symbol
  • Technology
    • BIOCHAPERONE®
    • Intellectual property
    • Publications
  • Products
    • Pipeline
    • BIOCHAPERONE® LISPRO
    • BIOCHAPERONE® COMBO
    • M1Pram
    • BIOCHAPERONE® GLUCAGON
    • BIOCHAPERONE® Gla GLP-1
    • BioChaperone® Glucagon GLP-1
    • Cell Therapy: AdoShell Islets
  • Partnering
    • Licensing Opportunities
    • Contact
  • Financials
    • Home Investors
    • Regulated Information
    • Documentation
    • Shareholders
    • Shareholders meeting
    • Governance
    • Investors Contact
  • Careers
    • Working at Adocia
    • HR Policy
    • Gender Equality index
    • Offers
  • News & Events
    • Press Releases
    • Upcoming Events

BioChaperone® Glucagon GLP-1

BIOCHAPERONE® GLUCAGON GLP-1 FOR THE TREATMENT OF OBESITY

Obesity is defined as an excessive accumulation of fat in adipose tissue negatively impacting the well-being and health of the person. A person is diagnosed as obese when his or her body mass index (BMI) is more than 30 kg/m². The increase in weight is the consequence of an imbalance between energy intake and expenditure. This imbalance results from a complex combination of environmental, behavioral and genetic factors.

The World Health Organization (WHO) estimates that there were 650 million obese adults in the world in 2016, or 13% of the world’s population.

Recent studies have shown that a multi-hormonal approach targeting both GLP-1 receptors and other metabolic hormone receptors, such as glucagon or GIP, could increase energy expenditure, promote significant weight loss and improve blood glucose control in obese people (Cegla G. et al, Diabetes 2014;63:3711–3720 ; Henderson SJ. et al , Diabetes, Obesity and Metabolism 2016; 18: 1176–1190; Evers A. et al, J Med Chem. 2017 May 25;60(10):4293-4303.)

A multi-hormonal approach

Based on this promising research and its BioChaperone Glucagon formulation, Adocia has developed BioChaperone Glucagon GLP-1, a two-in-one combination of human glucagon and exenatide (Byetta®, AstraZeneca), a GLP-1 receptor agonist. It has been previously shown that the combination of glucagon and GLP-1 RA works by increasing satiety, slowing gastric emptying and increasing energy expenditure.

Combined Effects of Glucagon and GLP-1 on Human Body

In contrast to the multi-agonist approaches, Adocia’s formulation approach makes it possible to rely on the efficacy and safety profiles of two approved molecules, while favoring the choice of the best ratio between these two molecules to optimize the product profile.

BIOCHAPERONE® GLUCAGON GLP-1 : STUDY

BioChaperone Glucagon GLP-1 is currently in preclinical development, with the goal of starting the first clinical trial in humans in 2020.

Products

  • Pipeline
  • BIOCHAPERONE® LISPRO
  • BIOCHAPERONE® COMBO
  • M1Pram
  • BIOCHAPERONE® GLUCAGON
  • BIOCHAPERONE® Gla GLP-1
  • BioChaperone® Glucagon GLP-1
  • Cell Therapy: AdoShell Islets

A la Une / Spotlight

  • 100 years ago, the first insulin injection saved Leonard Thompson

    This week, it has been 100 years since 14-year-...
  • Upcoming Investor Conferences – January 2022

    Dear investors, Adocia invites you to meet mana...

  • Home
  • Terms Of Use
  • Privacy Policy
  • Contact
ADOCIA a biotechnology company dedicated to protein delivery

Copyright ADOCIA © 2018

TOP